Effect of a biomimetic pathogen adsorbing device on inflammatory biomarkers in COVID‐19 patients.

Introduction: The Seraph 100 Microbind Affinity blood filter eliminate bacteria, viruses, fungi and toxins from blood stream. Methods: This is a prospective multicenter observational biomarker trial in PCR‐positive SARS‐CoV‐2 patients with acute respiratory failure. Biomarkers were sequentially tested at three time points. Results: Forty‐two patients with SARS‐CoV‐2 detected by PCR with acute respiratory failure were included. When receiving hemoperfusion treatment, 27 (64%) patients were on mechanical ventilation, 41 (98%) patients were treated in the ICU. The 3‐month survival was 52%. After one hemoperfusion treatment cycle, D‐dimer (p = 0.014), hemoglobin (p = 0.003) and LDH (p = 0.001) concentrations were significantly reduced 4 days after treatment. From the multiplex assay IL‐1b, CXCL8/ IL‐8, IL‐10, IL‐13, IL‐15, CCL11/Eotaxin, G‐CSF, and CXCL10/IP‐10 were significantly reduced 1 h after treatment, however not 4 days later. Conclusion: Hemoperfusion with Seraph 100 Microbind Affinity Filter in patients with severe COVID‐19 can transiently reduce several inflammatory biomarkers in the blood. [ABSTRACT FROM AUTHOR]